ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

Trials
Sue M CottonS Dodd

Abstract

First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown that the antioxidant amino acid N-acetylcysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary aim of this study is to determine the efficacy of treatment with adjunctive NAC (2 g/day for 26 weeks) compared with placebo to improve psychiatric symptoms in young people experiencing FEP. Secondary aims are to explore the neurobiological mechanisms underpinning NAC and how they relate to various clinical and functional outcomes at 26- and 52-week follow-ups. ENACT is a 26-week, randomised controlled trial of adjunctive NAC versus placebo, with a 26-week non-treatment follow-up period, for FEP. We will be recruiting 162 young people aged 15-25 years who...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jun 1, 1996·International Clinical Psychopharmacology·D V SheehanB A Raj
Apr 5, 2000·Journal of Neuropathology and Experimental Neurology·K RadewiczR Reynolds
Oct 13, 2000·The European Journal of Neuroscience·K Q DoM Cuénod
Jan 24, 2004·Journal of Manipulative and Physiological Therapeutics·Hugh Hurst, Jennifer Bolton
Jun 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wulf RösslerAnita Riecher-Rössler
Dec 7, 2005·The American Journal of Psychiatry·David L PennJeffrey A Lieberman
Feb 24, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Ashok K MallaRidha Joober
Oct 7, 2006·Acta Psychiatrica Scandinavica·G P AmmingerPatrick McGorry
Nov 16, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Suzie LavoieKim Q Do
Feb 4, 2010·The American Journal of Psychiatry·Alan S Brown, Elena J Derkits
Jul 21, 2010·Research in Nursing & Health·Denise F Polit, Brigid M Gillespie
Aug 3, 2010·Antioxidants & Redox Signaling·Kodavali V ChowdariVishwajit L Nimgaonkar
Sep 4, 2010·Journal of Clinical Psychopharmacology·Martin LambertBenno G Schimmelmann
Nov 12, 2010·Nature·Thomas R Insel
Dec 8, 2010·Schizophrenia Bulletin·Alan S Brown, Paul H Patterson
Dec 24, 2011·The American Journal of Psychiatry·Michael E BenrosPreben B Mortensen
Mar 2, 2012·Early Intervention in Psychiatry·John F M GleesonLouise McCutcheon
Jun 19, 2012·The American Journal of Psychiatry·Kevin M GrayKathleen T Brady
Oct 16, 2012·Biological Psychiatry·B J MillerAndrew Mellor
Nov 28, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·S DoddMichael Berk
Jan 9, 2013·Annals of Internal Medicine·An-Wen ChanDavid Moher
May 21, 2013·Biological Psychiatry·Joshua FlatowB J Miller
Oct 22, 2013·JAMA : the Journal of the American Medical Association·World Medical Association
Nov 10, 2013·Biological Psychiatry·Michael E BenrosPreben B Mortensen
Apr 8, 2014·Schizophrenia Research·Rachel UpthegroveNicholas M Barnes
Apr 29, 2014·Schizophrenia Research·Mónica Martínez-CengotitabengoaAna González-Pinto
Jul 23, 2014·Molecular Psychiatry·R S Kahn, I E C Sommer
May 11, 2015·Neuroscience and Biobehavioral Reviews·DeepmalaRichard Frye
Oct 17, 2015·The American Journal of Psychiatry·Peter S BloomfieldOliver D Howes
Oct 27, 2015·Social Psychiatry and Psychiatric Epidemiology·Sue M CottonPatrick McGorry
Dec 2, 2015·Bulletin of Experimental Biology and Medicine·S A IvanovaN A Bokhan
Jan 17, 2016·The Lancet. Psychiatry·Simon RosenbaumInternational Working Group
Mar 2, 2016·Schizophrenia Research·Allison S BrandtRussell L Margolis
Sep 10, 2016·The American Journal of Psychiatry·Sina HafiziRomina Mizrahi
Nov 30, 2016·Psychological Medicine·M Rapado-CastroOlivia May Dean
Mar 4, 2017·The British Journal of Psychiatry : the Journal of Mental Science·Michael BerkSue M Cotton
Mar 28, 2017·Psychiatry Research·Karine Maria BollEstefania Gastaldello Moreira
Mar 30, 2017·Translational Psychiatry·C F M G van KesterenI E C Sommer
Jun 3, 2017·The International Journal of Neuropsychopharmacology·David FraguasCelso Arango
Feb 8, 2018·Drug and Alcohol Dependence·Lindsay M SquegliaKevin M Gray
Mar 30, 2018·The International Journal of Neuropsychopharmacology·Círia PereiraOlivia May Dean
Apr 18, 2019·The Australian and New Zealand Journal of Psychiatry·Suzie LavoieStephen J Wood

Related Concepts

Acetylcysteine
Antioxidants
Bipolar Disorder
Blood
Chronic Disease
Glutathione
Inflammation
Magnetic Resonance Spectroscopy
Persons
Oxidation

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.